Literature DB >> 17404876

Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis.

Yoko Yokoyama1, Ken Fukunaga, Yoshihiro Fukuda, Katsuyuki Tozawa, Koji Kamikozuru, Kunio Ohnishi, Takeshi Kusaka, Tadashi Kosaka, Nobuyuki Hida, Yoshio Ohda, Hiroto Miwa, Takayuki Matsumoto.   

Abstract

Low-CD25(High+)CD4(+), a subset of regulatory CD25(+)CD4(+) T cells and high-inflammatory CD28(-)CD4(+) T cells can exacerbate ulcerative colitis (UC). This study sought to investigate the frequency of CD25(High+)CD4(+) and CD28(-)CD4(+) T cells in patients with UC and the changes in these cells during Adacolumn granulocyte and monocyte adsorption apheresis (GMA). Subjects were 12 patients with active UC, 11 with quiescent UC, and 14 healthy volunteers (HVs). The mean clinical activity index was 15.7 +/- 2.2 in active UC and 4.5 +/- 1.1 in quiescent UC. Peripheral blood samples were stained with CD4, CD25, and CD28 antibodies for flow cytometry. Patients with active UC received GMA and blood samples were examined before and after the first GMA session. Patients with active UC (P < 0.04) or quiescent UC (P < 0.02) had a higher percentage of CD28(-)D4(+)T cells compared with HVs, while the percentage of CD28(+)CD4(+) T cells was lower in both UC groups compared with HVs (P = 0.03 and P < 0.02). Patients with active UC had a lower percentage of CD25(High+)CD4(+)T cells compared with quiescent UC patients (P < 0.001). A significant increase in CD25(High+)CD4(+) T cells was associated with GMA (P < 0.03). Low CD25(High+)CD4(+) and high CD28(-)CD4(+) are prominent features in UC. The increase in CD25(High+)CD4(+) T cells induced by GMA should contribute to improved immune function. Additional studies are warranted, since a low frequency of CD25(High+)CD4(+) (-) and a high frequency of CD28(-)CD4(+) (-) expressing T cells might be a predictor of clinical response to GMA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404876     DOI: 10.1007/s10620-006-9560-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Absence of B7-dependent responses in CD28-deficient mice.

Authors:  J M Green; P J Noel; A I Sperling; T L Walunas; G S Gray; J A Bluestone; C B Thompson
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

2.  Expansion of unusual CD4+ T cells in severe rheumatoid arthritis.

Authors:  P B Martens; J J Goronzy; D Schaid; C M Weyand
Journal:  Arthritis Rheum       Date:  1997-06

3.  Neutrophil apoptosis is delayed in patients with inflammatory bowel disease.

Authors:  A E Brannigan; P R O'Connell; H Hurley; A O'Neill; H R Brady; J M Fitzpatrick; R W Watson
Journal:  Shock       Date:  2000-05       Impact factor: 3.454

4.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  CD28 costimulation promotes the production of Th2 cytokines.

Authors:  I C Rulifson; A I Sperling; P E Fields; F W Fitch; J A Bluestone
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

6.  CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells.

Authors:  Shin Makita; Takanori Kanai; Shigeru Oshima; Koji Uraushihara; Teruji Totsuka; Taisuke Sawada; Tetsuya Nakamura; Kazutaka Koganei; Tsuneo Fukushima; Mamoru Watanabe
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

7.  Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Abby R Saniabadi; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

8.  Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis.

Authors:  Katsuya Hiraishi; Yuji Takeda; Noriyuki Shiobara; Hiromu Shibusawa; Fumie Jimma; Nobuhito Kashiwagi; Abby R Saniabadi; Masakazu Adachi
Journal:  Ther Apher Dial       Date:  2003-06       Impact factor: 1.762

9.  Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis.

Authors:  Nobuhito Kashiwagi; Kazuhito Sugimura; Hirobumi Koiwai; Hironori Yamamoto; Toshikazu Yoshikawa; Abby R Saniabadi; Masakazu Adachi; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

10.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  21 in total

Review 1.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

2.  Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis.

Authors:  Grit Waitz; Sebastian Petermann; Stefan Liebe; Joerg Emmrich; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2008-02-06       Impact factor: 3.199

Review 3.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Inhibition of CXCL10 release by monomeric C3bi and C4b.

Authors:  Y Takeda; K Kaneda; F Jimma; N Shiobara; M Hidaka; A R Saniabadi; I Wakabayashi
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

5.  Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naïve patients with Crohn's disease.

Authors:  Kyoichi Kato; Ken Fukunaga; Koji Kamikozuru; Shinichiro Kashiwamura; Nobuyuki Hida; Yoshio Ohda; Naohisa Takeda; Koji Yoshida; Masaki Iimuro; Yoko Yokoyama; Risa Kikuyama; Hiroto Miwa; Takayuki Matsumoto
Journal:  Gut Liver       Date:  2011-03-16       Impact factor: 4.519

6.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

7.  The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.

Authors:  K Kamikozuru; K Fukunaga; S Hirota; N Hida; Y Ohda; K Yoshida; Y Yokoyama; K Tozawa; K Kawa; M Iimuro; K Nagase; A R Saniabadi; S Nakamura; H Miwa; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

8.  Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis.

Authors:  Shin-ichiro Takeda; Toru Sato; Tatsuro Katsuno; Tomoo Nakagawa; Yoshiko Noguchi; Osamu Yokosuka; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2009-11-12       Impact factor: 3.199

9.  Bacterial superantigens and T cell receptor beta-chain-bearing T cells in the immunopathogenesis of ulcerative colitis.

Authors:  N Shiobara; Y Suzuki; H Aoki; A Gotoh; Y Fujii; Y Hamada; S Suzuki; N Fukui; I Kurane; T Itoh; R Suzuki
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

Review 10.  Disrupted regulatory T cell homeostasis in inflammatory bowel diseases.

Authors:  Christophe Pedros; Fanny Duguet; Abdelhadi Saoudi; Marianne Chabod
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.